Liquid Biopsies – News and Features

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and progressing understanding of existing drugs.

Successful test in breast cancer patients: the active agent digoxin, a cardiac medication, dissolves clusters of circulating breast cancer cells in the blood, thus reducing the risk of metastases formation.

A new machine learning-powered blood test can detect multiple types of cancer in their earliest stages.

A study finds that a sensitive test detecting circulating tumour DNA (ctDNA) in early-stage lung cancer can predict relapse risk and survival. This approach could help doctors personalize treatment and improve patient outcomes.

A study has demonstrated that biomarker testing in smokers and ex-smokers can reduce lung cancer deaths by 40%. This large-scale trial highlights how measurable biological indicators enable earlier detection of lung cancer, improving survival rates.

University of Michigan researchers developed a biolaser-based method to detect circulating tumor cells in pancreatic and lung cancer patients. By combining cell lasers with machine learning, the technique identifies tumor cells with 99% accuracy.

For the first time, researchers have cultivated stable tumor organoids from circulating breast cancer cells, improving research into therapy resistance.

This article examines some of the latest advances in biomarker discovery in the fields of cancer and neurodegenerative and infectious diseases and the technologies that are driving these discoveries.

A new screening method that combines laser analysis with a type of AI is the first of its kind to identify patients in the earliest stage of breast cancer.

A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses.